Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe.

Abstract

Desmopressin is a potent antidiuretic for nocturnal enuresis with few and mostly insignificant adverse reactions. Almost 80 years ago, the antidiuretic effects of extracts of the posterior pituitary were first reported. The molecular structure of the peptide vasopressin arginine vasopressin (AVP) became known in 1956, and by 1967, a synthesized modification of AVP, known as DDAVP, or desmopressin, was introduced. Toxicity studies performed on experimental animals support the conclusion that desmopressin is considerably more potent as an antidiuretic than AVP and has an exceptional safety margin. Further, clinical experience reveals that from 1974 to June 1992 only 21 patients using desmopressin had serious adverse reactions (water intoxication), and no fatalities occurred. Seven of 10 children with nocturnal enuresis who receive desmopressin stop their bedwetting completely or reduce it significantly, with best results noted in children over 10 years of age. Given these results, the preferred treatment in Europe for children with nocturnal enuresis is the sequential combination of desmopressin and the enuresis alarm.

• Authors: K Hjälmås, B Bengtsson
• Journal: Clinical pediatrics (Clin Pediatr (Phila)) Vol. Spec No Pg. 19-24 (Jul 1993) ISSN: 0009-9228 [Print] United States
• PMID: 8039334 (Publication Type: Journal Article, Review)

Chemical References

• Deamino Arginine Vasopressin

Topics

• Adolescent
• Animals
• Child
• Deamino Arginine Vasopressin (adverse effects, therapeutic use, toxicity)
• Dose-Response Relationship, Drug
• Enuresis (drug therapy)
• Europe
• Humans